Back to Search
Start Over
A dual drug-loaded peptide system with morphological transformation prolongs drug retention and inhibits breast cancer growth.
- Source :
-
Biomaterials advances [Biomater Adv] 2023 Nov; Vol. 154, pp. 213650. Date of Electronic Publication: 2023 Oct 17. - Publication Year :
- 2023
-
Abstract
- The treatment of breast cancer relies heavily on chemotherapy, but chemotherapy is limited by the disadvantages of poor targeting, susceptibility to extracellular matrix (ECM) interference and a short duration of action in tumor cells. To address these limitations, we developed an amphipathic peptide containing an RGD motif, Pep1, that encapsulated paclitaxel (PTX) and losartan potassium (LP) to form the drug-loaded peptide PL/Pep1. PL/Pep1 self-assembled into spherical nanoparticles (NPs) under normal physiological conditions and transformed into aggregates containing short nanofibers at acidic pH. The RGD peptide facilitated tumor targeting and the aggregates prolonged drug retention in the tumor, which allowed more drug to reach and accumulate in the tumor tissue to promote apoptosis and remodel the tumor microenvironment. The results of in vitro and in vivo experiments confirmed the superiority of PL/Pep1 in terms of targeting, prolonged retention and facilitated penetration for antitumor therapy. In conclusion, amphipathic peptides as coloaded drug carriers are a new platform and strategy for breast cancer chemotherapy.<br />Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.<br /> (Copyright © 2023 Elsevier B.V. All rights reserved.)
Details
- Language :
- English
- ISSN :
- 2772-9508
- Volume :
- 154
- Database :
- MEDLINE
- Journal :
- Biomaterials advances
- Publication Type :
- Academic Journal
- Accession number :
- 37857084
- Full Text :
- https://doi.org/10.1016/j.bioadv.2023.213650